Stockscreener 앱 받기
10.19
0.00%
0.00
전일 마감가:
$10.19
열려 있는:
$10.2
하루 거래량:
264
Relative Volume:
0.01
시가총액:
$219.06M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.10%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.19
$10.20
1주일 범위
$10.13
$10.29
52주 변동 폭
$10.13
$10.35
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
Compare HLXC vs CCXI, LION, XXI, CCCX, DMII
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HLXC
Helix Acquisition Corp Iii
|
10.19 | 219.06M | 0 | 0 | 0 | 0.00 |
|
CCXI
Churchill Capital Corp Xi
|
10.19 | 3.64B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.09 | 2.31B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
6.40 | 2.01B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.66 | 687.84M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.99 | 655.09M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii 주식(HLXC)의 최신 뉴스
Can AIFER ride the EV waveQuarterly Profit Review & Free Long-Term Investment Growth Plans - mfd.ru
Newsroom - White & Case LLP
Helix Acquisition Corp. III completes $172.5 million IPO and private placement - Investing.com Nigeria
Helix Acquisition Corp. III Completes Initial Public Offering - TradingView
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Helix Acquisition prices $150M initial public offering - MSN
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
Helix Acquisition Corp III closes $172.5 million IPO - Investing.com
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
New startup to develop a GLP-1 drug for addiction - statnews.com
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Insider Buy: Does Unusual Machines Inc align with a passive investing strategyTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - intellectia.ai
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
HLXC IPO NewsCormorant's SPAC Helix Acquisition III files for a $125 million IPO, targeting healthcare - renaissancecapital.com
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com
SPACs Line Up To Clear Biotech’s IPO Backlog - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - The Globe and Mail
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Nigeria
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - FinancialContent
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Big Law Firms Wary of SPAC Rebound Seek to Get Paid This Time - Bloomberg Law News
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group - TheNewswire
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Bay Area VC-funded life sciences companies raised over $5 billion in 2024 - The Business Journals
Checkpoint checks out | ApexOncoClinical Trials news and analysis - Oncology Pipeline
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
Life Sciences Hedge Fund Perceptive Preps a New SPAC - Institutional Investor
Helix Acquisition Corp. II Closes of $184 Million IPO - citybiz
Helix Acquisition Corp. II Prices of Upsized $160 Million IPO - citybiz
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace
MoonLake Immunotherapeutics goes public via SPAC - Startupticker.ch
Moonlake going after blockbuster indications with dual-targeting nanobody - BioWorld MedTech
SPAC Market Remains Hot as MoonLake Therapeutics Hits the Nasdaq - BioSpace
Helix Acquisition Corp Iii (HLXC) 재무 분석
Helix Acquisition Corp Iii (HLXC)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.00%
0.29%
자본화:
|
볼륨(24시간):